Biopelle, Inc., is a worldwide leader in the development and distribution through skincare professionals of clinically proven, high quality, cost-effective aesthetic products that promote skin rejuvenation and wellness.
Biopelle was established as the aesthetic division of Ferndale Laboratories, Inc. in August 2005 and incorporated as a subsidiary of the Ferndale Pharma Group, Inc. in April 2007. Charged with the task of developing a unique product portfolio to improve the health and appearance of the skin, Biopelle has developed, licensed, or acquired unique, patented technologies that target multiple metabolic pathways to address demanding skin and deliver visible results. Biopelle’s philosophy of proper skincare is centered on the principle that the optimal skincare regimen addresses as many metabolic pathways as possible. Biopelle leads the industry in pathway innovation.
Biopelle’s impressive growth in the aesthetic market is a direct result of its dedication in ensuring it delivers value by:
- helping its customers realize the full aesthetic potential of their patients and clients
- delivering “a global spectrum of skin care products” that target multiple pathways
- funding aesthetic research and education
- providing exceptional customer service
Biopelle does this through its distribution of evidence-based, cosmetically elegant professional products through licensed Healthcare Providers. Biopelle’s brands cover its “global spectrum of skin care” through its two main pillars:
- Biopelle® (including Retriderm®, Tensage® Growth Factor and Tensage® Stem Cell with Cellpro™ Technology – the newest pathway of rejuvenation)
- PRESCRIBEDsolutions®, the only multi-tasking customizable skincare line with boosters
Biopelle is also the US distributor to healthcare professionals for the peri-procedure products, LMX4® and Auriderm®.
For more information, visit www.biopelle.com